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Background:  
The increased storage iron level is connected to a higher frequency of cardiovascular events (CVE). 
Aims and hypothesis: 
The study investigates the relationship between LIP (labile iron pool) in circulating monocytes and 
markers of iron metabolism and atherosclerosis (inflammation, oxidative stress, endothelial dysfunction 
and arterial elasticity) in patients with chronic cardiovascular disease and in healthy volunteers and in 
long-term blood donors and healthy non-donor volunteers. 
Methods: 
A detailed medical history was obtained from the probands and anthropometric measurements (body 
height, weight and waist, calculation of body mass index and waist-hip ratio) were performed. The 
following parameters were measured / calculated for all respondents: blood pressure (systolic / 
diastolic), ankle-brachial index (ABI), pulse pressure and mean arterial pressure, cardio-ankle vascular 
index (CAVI), augmentation index (AI), pre-ejection time (PEP) and ejection time (ET), sonographic 
examination of abdomen and carotid arteries were performed. Blood samples were collected in the 
morning after at least 10 hours of fasting. We performed a basic biochemical examination and measured 
the parameters of inflammation, endothelial dysfunction, oxidative stress. We measured LIP levels in 
isolated monocytes. 
Results:  
The patients with a history of CVEs had significantly higher LIP values than did the control group 
(1.94±0.46 µM vs. 1.62±0.49 µM, p=0.02). Except for the leukocyte number, the groups did not differ in 
other inflammatory markers (CRPus, CD 163, MPO, MMP-1). Similarly, there were no differences in the 
markers of endothelial dysfunction (ICAM, VCAM, E-selectin, vWF). The CVE group had higher pulse 
pressures, levels of markers of impaired arterial elasticity (AI, Young´s modulus, pulsatility, stiffness 
index), IMT values and ABI values. The LIP concentration was significantly correlated with the transferrin 
receptor⁄ferritin ratio, hepcidin levels, visceral fat tissue content and the ABI and ET (ejection time) 
values. Further analysis showed that the OR for acute CVE was 6 fold higher when LIP tertiles were 
compared (OR=5.96, P=0.0156). 
We found that donors had significantly higher LIP values than the control group (1.84 ± 0.44 uM vs. 1.50 
± 0.41 uM, p = 0.017). Despite the observed tendency for the donor group to have higher blood 
pressure, cholesterol, glucose and HOMAR-IR, the groups did not differ in inflammatory markers, 
markers of endothelial dysfunction and markers of impaired arterial elasticity. The donor group had 
significant changes in iron metabolism (higher serum Fe, ceruloplasmin, and transferrin receptor/ferritin 
ratio and lower hepcidin, ferritin, and CD163), indicating depletion of body iron stores and activation of 
iron turnover. 
Conclusions:  
Patients with a history of CVE have significantly higher concentrations of intracellular LIP in circulating 
monocytes than do healthy controls. The independent and significant correlation of LIP with markers of 
the progression of atherosclerosis and arterial stiffness suggests LIP as a possible marker of 
atherosclerotic activity in patients with chronic cardiovascular disease. 
LIP seems to be a good marker of iron turnover activity in donor group. We did not find a significant 
correlation between LIP levels and atherosclerosis progression between donor and non-donor group. 
However, further studies are needed to assess long-term donorship as a protective factor against 
atherosclerosis. 
